Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind randomized steroid-controlled study of GGS in optic neuritis
jRCT2080222034Phase 3Completed
- Sponsor
- Teijin Pharma
- Start
- Mar 2013
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sulfonated human normal immunoglobulin in optic neuritis (ON) (2 arms), sponsored by Teijin Pharma. Primary endpoint: Visual acuity improvement. Started Mar 2013; status: completed.
02
Drugs
sulfonated human normal immunoglobulin
03
Conditions
optic neuritis (ON)
Beyond the preview
Go deeper on jRCT2080222034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222034.